Our latest articles
A couple of small M&A deals this week shows more developers capitulating to the new reality.
A clinical hold for the company’s Exondys 51 follow-on adds further pressure on the forthcoming gene therapy readouts.
Pivotal data will show whether KarXT can walk the risk-benefit tightrope.
A look at blockbuster origins shows the role of external innovation, but more of these huge franchises are in the hands of their inventors than ever before.
A surprise move into the Car-T space suggests the beleaguered Belgian biotech still has an eye on its rich benefactor.
Real world data on Translarna look good but with a failed confirmatory trial and a troubled history, US approval is far from guaranteed.
Medtronic, Siemens and Stryker are all expected to seize greater market share, while Roche slides down the rankings.
If Jemperli might effectively cure a biomarker-defined subset of rectal cancer patients why isn't pharma more interested?
But a surprise adcom for omecamtiv mecarbil might put a spanner in the works.
Some medtech venture investors are taken with the promise of digital technologies, while others find them easy to resist.